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Abstract	
Two of the world’s most neglected tropical diseases, human African trypanosomiasis (HAT) and 
Chagas Disease, are caused by protozoan parasites of the genus Trypanosoma. These organisms 
possess specialised metabolic pathways, frequently distinct from those in humans, which have 
potential to be exploited as novel drug targets. This study elucidates the structure and function of L-
threonine-3-dehydrogenase (TDH) from T. brucei, the causative pathogen of HAT.  TDH is a key 
enzyme in the metabolism of L-threonine, and a TDH inhibitor has been shown to have trypanocidal 
activity.  TDH in humans is a non-functional pseudogene, suggesting that it may be possible to 
rationally design safe and specific therapies for trypanosomiasis by targeting this parasite enzyme.  
As an initial step, the TDH gene from T. brucei has been expressed, and the three-dimensional 
structure of the enzyme has been solved for the first time by X-ray crystallography.  In multiple 
crystallographic structures, T. brucei TDH is revealed to be a dimeric short-chain dehydrogenase that 
displays a considerable degree of conformational variation in its ligand binding regions.  Geometric 
simulations of the structure have provided insight into the dynamic behaviour of this enzyme. 
Furthermore, the structures of TDH bound to its natural substrates and known-inhibitors have been 
determined, giving an indication of the mechanism of catalysis of the enzyme.  Collectively, these 
results provide vital details for future drug design to target TDH or related enzymes. 
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Introduction	
Trypanosomiasis is a human and animal disease caused by infection with insect-transmitted 
parasites of the genus Trypanosoma, protozoa distinguished by a single flagellum.  In humans, 
Trypanosoma brucei causes human African trypanosomiasis (HAT), which is endemic in sub-Saharan 
Africa, and Trypanosoma cruzi causes Chagas disease, which is widespread in South America.  HAT is 
fatal if left untreated, whilst Chagas disease often results in chronic and life-threatening pathology 
many years after the initial infection[1,2]. 
Both HAT and Chagas disease have been designated as Neglected Tropical Diseases (NTDs).  These 
debilitating infections often affect poorer populations within developing countries, and have 
historically received less attention for pharmaceutical R&D. As a result, there are a limited number 
of drugs available for both diseases, and these have numerous shortcomings, which include toxicity, 
limited efficacy, and acquisition of resistance by the pathogens.  Developing a more detailed 
understanding of Trypanosoma biochemistry and metabolism should aid the identification of new 
drug targets.  
The main hypothesis of this project is that a genetic difference between trypanosomes and their 
human hosts is exploitable for drug design. It is known that the insect gut form of T. brucei 
selectively and rapidly metabolises L-threonine by the action of L-threonine 3-dehydrogenase (TDH). 
Indeed, inhibitors of TDH are lethal to the parasite[3,4]. More recent work has shown that TDH is a 
pseudogene and non-functional in humans, and that an alternative metabolic pathway exists [5]. 
This suggests that inhibitors of trypanosome TDH may have potential as highly specific anti-parasitic 
agents. Recent work using reverse genetics has shown that glucose and threonine contribute almost 
equally to Ac-CoA production, both being crucial in  bloodstream form (BSF) and procyclic form 
parasites, with blockade of the corresponding pathways inducing cell death[6,7]. Hence we 
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expressed and crystallised T. brucei TDH, and derived its crystal structure at high resolution with 
various physiological ligands bound.  
 
There are three known pathways of threonine catabolism, which are initiated by L-threonine 
aldolase (EC 4.1.2.5), L-threonine dehydratase (also known as L-threonine deaminase; EC 4.2.1.16) 
and L-threonine 3-dehydrogenase (TDH; EC 1.1.1.103)., which is the dominant pathway in several 
prokaryotes and eukaryotes[5,8,9].  The activity of L-threonine aldolase has been shown to be low or 
insignificant in prokaryotes[10] and eukaryotes[11] and no expression of the enzyme has been 
detected in humans[12].  In contrast, the pathway initiated by L-threonine dehydratase is a major 
mechanism for L-threonine catabolism and can become the dominant pathway in certain metabolic 
states in animals[11].  The other major route for L-threonine catabolism is initiated by the 
mitochondrial matrix enzyme TDH, and appears to be the dominant pathway in many prokaryotes 
and eukaryotes[5,8,9].  In this pathway, TDH works in tandem with a second enzyme, 2-amino-3-
ketobutyrate ligase (KBL) to catabolise L-threonine to glycine and Ac-CoA (Figure 1). 
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Figure 1.The L-threonine degradation pathway. The enzyme TDH oxidises L-threonine to 2-amino-3-ketobutyrate (AKB).  
KBL then converts AKB to glycine and Ac-CoA.  Alternatively, AKB may undergo spontaneous breakdown to 
aminoacetone and carbon dioxide. 
In the first part of this process, TDH oxidises L-threonine to 2-amino-3-ketobutyrate (AKB) in a 
reaction dependent on NAD(H).  There is evidence that AKB is unstable and spontaneously breaks 
down to aminoacetone and carbon dioxide.  Thus it has been suggested, backed by other evidence,  
that TDH and KBL form a multi-enzyme complex to facilitate the completion of the second reaction, 
the breakdown of AKB to Ac-CoA and glycine by KBL[8,13]. 
 
TDH belongs to an enzyme family that is sub-divided into short-chain (SDR), medium-chain (MDR) 
and long-chain (LDR) dehydrogenase/reductases[14].  Several of the most studied TDHs have been 
MDRs, showing a tetrameric quaternary structure and a requirement for divalent metal cations, such 
as zinc(8,19–23).  More recently, a second group of TDH enzymes that share features with UDP-
galactose 4’-epimerase have been characterised.  These enzymes belong to the SDR family, and in 
contrast to the MDR TDH enzymes, they are dimeric and have no requirement for divalent 
cations(24–26).  KBL has not been studied to the same extent, but the crystallographic structure of 
the enzyme from Escherichia coli has been published[23]. 
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The L-threonine degradation pathway catalysed by TDH and KBL plays a variety of roles in both 
prokaryotes and eukaryotes, including energy production, homeostasis and fatty acid synthesis.  The 
pathway and its constituent enzymes have been studied in T. brucei, but crystal structures of the 
enzymes are yet to be published. 
T. brucei was shown by Cross et al. to preferentially and exhaustively consume L-threonine when 
grown in mixed media[3].  Furthermore, it was shown that most of the absorbed threonine was 
catabolised via the TDH pathway, producing Ac-CoA and glycine.  To further underline the 
importance of this pathway, exposure of cultured T. brucei to tetraethyl thiuram disulphide (TETD), 
an inhibitor of human aldehyde dehydrogenase and a potent inhibitor of TDH, has been 
demonstrated to lead to trypanosome death in correlation with the degree of TDH inhibition[3,4].   
A principal reason for the detrimental effect of TDH inhibition on T. brucei is the importance of the 
pathway for fatty acid synthesis, for which Ac-CoA is a substrate.  Millerioux, Mazet and colleagues 
have demonstrated that Ac-CoA is required for fatty acid synthesis by simultaneously inhibiting TDH 
and another key Ac-CoA-producing enzyme, pyruvate dehydrogenase, which proved to be 
lethal[6,7].  The physiological role of L-threonine metabolism through the TDH pathway is not 
limited to fatty acid production and there may be additional functions not yet elucidated.  For 
instance, glycine produced from L-threonine by TDH in T. brucei has been shown to be incorporated 
into trypanothione[6], an antioxidant analogous to glutathione found in humans.  In addition, 
studies of 13C-labelled glucose metabolism in BSF T. brucei showed that glucose-derived acetate was 
used to acetylate amino acids, and it was suggested that L-threonine-derived acetate plays a role in 
this process [24].  
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Below, we present the first complete description of the tertiary and quaternary structure of TbTDH, 
as analysed by X-ray crystallography and a range of other biochemical and computational 
techniques. The results give insight into the relationship between TDH and its natural cofactor and 
substrate, and also the relationship between TDH and the subsequent enzyme in the pathway, KBL. 
 
Results	
Structure	of	TDH	
Crystal	growth	and	Data	Collection	
Diffracting TDH crystals were successfully grown under a number of different conditions, which are 
listed in Table 1, along with data collection and refinement statistics for the related data sets. 
Diffracting TDH crystals were cryo-cooled using glycerol, PEG 400 or ethylene glycol.  It was also 
possible to collect quality data from crystals cooled in the absence of cryoprotectant, as exemplified 
by the data used to solve two structures (PDB ID: 5K4W and PDB ID: 5K4Y).   
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Table 1. Details of data collected and structures solved by X-ray crystallography 
 Model 
RCSB PDB ID 5L9A 5LC1 5K4Q 5K4T 5K4V 5K4U 5K50 5K4W 5K4Y 
Crystallisation Conditions          
Conditions 
0.1 M 
HEPES; 20 
% w/v PEG 
10K; pH 7.5; 
TDH (5.28 x 
10-2mM [2.0 
mg/ml]) 
0.1 M 
HEPES; 20 
% w/v PEG 
10K; pH 7.5; 
TDH (5.28 x 
10-2mM [2.0 
mg/ml]); 
NAD+ 
(1mM); 
pyruvate 
(30mM) 
0.2M lithium 
sulphate; 
0.1M Tris; 
30% w/v 
PEG 4K; pH 
8.5; 
TDH (6.4 x 
10-2mM 
[2.4mg/ml]); 
KBL (3.8 x 
10-2mM 
[1.8mg/ml]); 
NAD+ 
(0.09mM); 
PLP 
(0.18mM);  
L-Threonine 
(7.33mM) 
0.1M MES; 
0.2M 
ammonium 
sulphate; 
30% w/v 
PEG 5K 
MME; pH 
6.5; 
TDH (9.0 x 
10-2mM 
[3.4mg/ml]);  
L-serine 
(50mM) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
8.5;  
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(10mM); 
BPOB 
(0.5mM) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
5.6; 
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(8.5mM); 
quinine 
(2.5mM 
[hydrochlorid
e 
dehydrate]) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
5.6; 
TDH (10.4 x 
10-2mM 
[3.9mg/ml]); 
NAD+ 
(10mM); L-
allo-
threonine 
(30mM) 
0.2M sodium 
acetate; 
0.1M Tris; 
30% w/v 
PEG 4K; pH 
8.5; 
TDH (9.3 x 
10-2mM 
[3.5mg/ml]); 
NADH 
(10mM);  
L-Threonine 
(30mM) 
0.1M tri-
sodium 
citrate; 25% 
w/v PEG 
4K; 0.2M 
ammonium 
acetate; pH 
5.6 
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(10mM); 
methylglyox
al (8mM) 
Cryoprotectant Glycerol Glycerol Glycerol Glycerol Glycerol Glycerol Glycerol None None 
Data Collection          
Beamline ESRF ID23-2 ESRF ID29 ESRF DLS I04-1 DLS I04-1 DLS  DLS I04-1 DLS I02 DLS I04-1 
Wavelength (Å) 0.8726 1.07356 0.9334 0.9173 0.9173 0.9173 0.92 0.9795 0.92001 
Space group P1 P21212 P21212 P43212 P21212 P21212 P21212 P21212 P21212 
Unit cell parameters          
a (Å) 46.98 132.03 132.04 91.76 90.40 90.07 133.03 83.45 133.45 
b (Å) 57.72 276.49 276.49 91.76 131.53 133.10 273.06 136.12 278.63 
c (Å) 70.07 55.74 55.74 93.60 55.02 55.61 55.80 55.69 56.27 
α (°) 72.46 90 90 90 90 90 90 90 90 
β (°) 70.38 90 90 90 90 90 90 90 90 
γ (°) 73.2 90 90 90 90 90 90 90 90 
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 Model 
RCSB PDB ID 5L9A 5LC1 5K4Q 5K4T 5K4V 5K4U 5K50 5K4W 5K4Y 
Max. resolution (Å) 1.45 2.1 2.3 2.1 2.2 1.9 2.26 1.72 1.77 
No. of reflections 409937 874324 624537 301645 109277 203173 297998 435135 438691 
No. of unique reflections (used) 109054 117204 93173 23982 32475 61881 91289 67909 193067 
Solvent content (%) 44.2 45.05 46.34 52.83 42.88 43.94 44.98 41.24 46.7 
Matthews coefficient (Å3.Da-1) 2.2 2.24 2.29 2.61 2.15 2.19 2.23 2.09 2.31 
Resolution range (Å) 53.82 - 1.45 95.48 - 2.10 48.143 - 2.3 29.073 - 2.1 28.226 - 2.2 28.552 - 1.9 31.09 - 2.26 46.32-1.72 39.60 - 1.77 
Multiplicity 3.8 7.5 6.7 12.6 3.4 3.3 1.9 6.4 6.2 
Completeness (%) 95 97.3 99.188 99.98 95 97.7 90.4 99.5 99.6 
Mean I/σ 10.4 11.4 11.2 33.6 13.4 12.7 5.6 11 12.6 
Rmerge 0.089 0.145 0.12 0.054 0.067 0.074 0.151 0.094 0.121 
Rpim 0.051 0.055 0.049 0.016 0.04 0.048 0.181 0.04 0.055 
Rmeas 0.103 0.156 0.13 0.056 0.079 0.088 0.214 0.102 0.133 
Refinement          
Rwork 0.1649 0.181 0.1746 0.1741 0.1643 0.1864 0.2073 0.1522 0.16071 
Rfree 0.2218 0.2873 0.2618 0.2400 0.2411 0.2321 0.2809 0.1976 0.20074 
RMS bond lengths (Å) 0.011 0.008 0.0178 0.0245 0.0201 0.0241 0.0128 0.0198 0.0201 
RMS bond angles (°) 2.198 1.837 1.764 2.059 1.826 1.99 1.6492 2.1037 1.9749 
Average B-factor (Å2) 18.68 22.2 21.09 26.769 26.234 22.138 33.76 27.689 19.218 
Ramachandran favoured, % of 
total 696, 97.6% 1872, 97.0% 
1830, 
96.62% 309, 96.87% 613, 96.69% 618, 97.48% 
1801, 
95.14% 622, 97.65% 
1824, 
97.91% 
Ramachandran allowed, % of 
total 711, 99.7% 1923, 99.6% 61, 3.22% 8, 2.51% 18, 2.84% 14, 2.21% 82, 4.33% 13, 2.04% 33, 1.77% 
Ramachandran outliers, % of 
total 2, 0.3% 7, 0.4% 3, 0.16% 2, 0.63% 3, 0.47% 2, 0.32% 10, 0.53% 2, 0.31% 6, 0.32% 
Molecules in the asymmetric unit 2 6 6 1 2 2 6 2 6 
Quaternary structure Dimer Dimer Dimer Dimer Dimer Dimer Dimer Dimer Dimer 
Residue range His1-Leu321 His1-Leu321 Pro3-Leu321 His1-Leu321 Pro3-Leu321 Pro3-Leu321 Pro3-Leu321 His1-Leu321 Met2-Leu321 
No. protein atoms per monomer 2621 2511 2493 2532 2493 2493 2500.5 2507 2533 
No. water molecules per 
monomer 651 328 252.3 152 220.5 100.5 73.7 210 241.1 
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 Model 
RCSB PDB ID 5L9A 5LC1 5K4Q 5K4T 5K4V 5K4U 5K50 5K4W 5K4Y 
NAD+ bound? No Yes Yes No Yes Yes Yes Yes (NADH) Yes 
Ligands bound, Mean B-factor - 
Pyruvate, 
33.66  
NAD, 18.37 
- - - - 
L-allo-
threonine, 
39.53 
L-allo-
threonine, 
26.88 
L-threonine, 
26.06 
L-threonine, 
30.58 
- 
Other solvent molecules/ions acetate acetate glycerol, sulphate glycerol 
glycerol, 
acetate, Na+ 
glycerol, 
acetate 
glycerol, 
acetate glycerol, Na
+ glycerol, acetate 
Conformation(s) of flexible 
Loop 1 Open Closed Open Open Closed 
Open and 
Closed 
Open and 
Closed Closed Open 
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TbTDH	primary	and	secondary	structure	
The TDH sequences from T. brucei strain TREU 927 and T. brucei gambiense are essentially identical, 
confirming that the TDH studied in this work is relevant to a human pathogen. The animal pathogen 
T. congolense has a protein that shares 78% sequence identity with the TDH studied here. The 
sequence identity between TDH from T. brucei strain TREU 927 and the Chagas disease-causing 
pathogen, Trypanosoma cruzi, is 72%. Thus, TDH from a range of Trypanosoma species are closely 
related (Supplementary Figure 1). 
Other TDH enzymes with a high sequence similarity to TbTDH include the UDP-galactose 4’-
epimerase-like (GalE) TDH enzymes from Thermoplasma volcanium, Flavobacterium frigidimaris and 
Cupriavidus necator. The corresponding enzymes from these organisms have monomeric molecular 
weights between 35 and 37.2kDa, matching that of TDH from T. brucei (37.8 kDa). Another group of 
related TDH enzymes originate from mammalian species: Gallus gallus (red junglefowl), Rattus 
norvegicus (rat), Sus scrofa (boar/pig) and Capra hircus (goat). Once again, TDH enzymes from these 
species have been studied previously and shown to have molecular weights in the range of 36 
kDa[25] to 37 kDa [26]. 
Inspection of the sequences of the various TDHs shows that they belong to the SDR superfamily of 
enzymes. Two highly conserved structural features that can be identified from the sequence are 
highlighted in Supplementary Figure 2. The first, a glycine-rich region, is represented by the 
sequence GxxGxxG, and the second consists of a tyrosine and a lysine residue separated by three 
other residues: YxxxK. 
 
X-ray models of TbTDH revealed that each individual subunit consists of two domains displaying α/β 
topology. The distribution of secondary structure elements in TDH appears to be approximately 38% 
α-helix and 12% β-sheet, with the remaining 50% of the protein not forming specific folds. 
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Figure 2.TbTDH coloured by secondary structure (gold = α-helix; dark green = β-strand; light blue = loop).  Cartoon 
representation produced using UCSF Chimera. 
TbTDH	tertiary	structure	
TbTDH encompasses an NAD-binding domain, which includes the first 180-200 amino acids, and a 
catalytic domain at the C-terminal end of the protein (Supplementary Figure 3). In three dimensions, 
there is some crossover between these domains. There is a Rossmann fold motif (parallel β-strands 
flanked by α-helices), which is characteristic of NAD-binding proteins, and hence SDRs.  The 
structural motif GxxGxxG, which is common to the ‘extended’ class of SDRs (eSDR), is located within 
the NAD binding region and is represented by the sequence Gly9-Ala10-Leu11-Gly12-Gln13-Ile14-
Gly15. This motif is involved in binding the diphosphate group of NAD (Figure 6). The YxxxK motif 
and several other conserved residues, including Met81, Ser82, Thr119, Thr186, Trp280, and Tyr144 
and Lys148 of the SDR YxxxK motif are located in the active site (Figure 7). 
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When comparing the different crystallographic models, which were obtained with different ligands 
and crystallised in different space groups, no large domain movements were observed.  By 
comparing corresponding residues on different TDH models, it was possible to detect a certain 
degree of variation in the relative positions of certain atoms (see methods), as indicated by the root-
mean-square deviation (RMSD).  Furthermore, an analysis of the average B-factor for each residue 
revealed high B-factors for some residues, supporting the notion that those regions of the protein 
are more disordered than others, and thus more flexible.  
 
Figure 3. Conformational flexibility as indicated by RMSD of Cα positions of the different TbTDH structures (PDB ID: 
5K4Q; PDB ID: 5K4T; PDB ID: 5K4V; PDB ID: 5K4U; PDB ID: 5K50; PDB ID: 5K4W) when superimposed in UCSF Chimera. (a) 
A ribbon representation of TDH, coloured by the RMSD of α-carbon positions in each residue. The scale at the bottom of 
the diagram indicates the colour scheme relating to the RMSD measured in Ångstrom. (b) A bar chart showing the RMSD 
of α-carbons per TDH residue. 
A number of regions in TbTDH appear to be flexible (Figure 3). Firstly, there are two disordered loop 
regions: Loop 1 includes residues Thr179 and Ala185, and Loop 2 lies between residues Asp35 and 
Asn60. There also appears to be a higher degree of flexibility in the catalytic domain (gold and red-
coloured region on the right-hand side of Figure 3a). The most striking evidence of conformational 
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variability is found in the residues of Loop 1. Indeed, in different crystallographic structures, this loop 
was found to occupy two distinctive positions: one where the loop was in an ‘open’ position, lying at 
a distance of approximately 5 Å  from the active site, and another where the loop was ‘closed’ and 
positioned adjacent to the active site (Figure 4). Therefore, for each model of a TDH monomer, the 
structure can be classified as ‘open’ or ‘closed’, on the basis of the conformation of Loop 1.  
Comparing the average B-factors in the open and closed structures highlighted changes in flexibility 
or disorder that accompanied the change in the Loop 1 conformation. For example, Figure 4b shows 
the average B-factors of TDH residues in ‘open’ structures, whilst Figure 4c shows the average B-
factors for the ‘closed’ structures. 
 
Figure 4. A colour representation of the average B-factors of TDH residues, derived from structures PDB ID: 5K4Q, PDB 
ID: 5K4T, DB ID: 5K4V, PDB ID: 5K4U, PDB ID: 5K50 and PDB ID: 5K4W. (a) A ribbon diagram of TDH coloured by residue-
average B-factor (scale in horizontal bar).  The distinct 'closed' position of Loop 1 is displayed in red. (b) A chart showing 
the average B-factor of residues in 'open' TDH structures. (c) A chart showing average B-factors of TDH residues in 
‘closed’ structures 
In the ‘open’ structures, the highest B-factors are seen around both loop regions. However, in the 
closed structures, although these same residues have above average B-factors, they are much less 
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disordered. Inspection of Figure 4c demonstrates that the catalytic domain appears to be more 
disordered in closed structures. In three dimensions, this region can be seen as one of a pair of 
adjacent α-helices and β-strands, which are the gold-coloured regions on the right hand sides of the 
structures in Figure 3a and Figure 4a. 
The NAD-binding region, particularly around Loop 2, also appears to be flexible. Although the B-
factors are low, the RMSDs around residues 82 to 100 are particularly high (Figure 3b). This region 
lies at the dimerization interface (discussed below), indicating some conformational variability there.   
These findings indicate that there may be a relationship between the conformation of Loop 1, and 
the flexibility of other regions of the protein, particularly the catalytic domain. The different 
conformational changes do not appear to correlate with the space-group of the crystal (Table 1). 
Thus, the specific conformation of Loop 1 and the flexibility of the catalytic region may actually be 
influenced by ligand binding. Indeed, three of the four ‘closed’ structures (from PDB ID: 5K4U, PDB 
ID: 5K4W and PDB ID: 5K50) examined were bound to NAD/NADH and another ligand, whilst only 
one of the four ‘open’ structures (from PDB ID: 5K50) examined possessed bound NAD and another 
ligand.  
 
TbTDH	quaternary	structure	and	complex	formation	
TDH was shown to exist as a dimer following refinement of all the X-ray crystallographic models. The 
dimerization interface consists of two α-helices (Pro89-Tyr110 and Val143-Tyr162) and a loop 
(Lys126-Thr142), with the same regions on each monomer making contact in the dimer. As can be 
seen in Figure 5, the dimer is stabilised by a large number of hydrophobic, polar and ionic 
interactions. In particular, polar side chains of residues on each monomer form hydrogen bonds with 
each other and charged residues form salt bridges. Interactions across this interface include the 
following: Glu86 with Trp157; Asp90 with Arg101; Asp94 with Arg101; Lys126 with Asp135. This 
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probably gives greater stability to the dimer, whilst the length of some of the side chains allows their 
interactions to be maintained in the case of any change in the orientation of the two monomers. 
 
Figure 5. The TDH dimer and its dimerisation interface.  Lines between amino acids indicate Van der Waals, polar or ionic 
interactions. Key residues involved in the interaction include Glu86, Asp90, Asp94, Arg101, Lys126, Asp135 and Trp157 
Further evidence of the existence of the dimer and that this is the largest oligomer present in all of 
the crystallographic structures, was provided using the software PISA[27].  Supplementary Table 1 
lists a number of different interfaces between different TDH subunits in the different structural 
models and it can be seen that the only stable association predicted by PISA is the dimer relationship 
previously described. There is no clear relationship between the crystal space group and the nature 
of the dimerisation interface. 
 
Oligomerisation	studies	
When assayed separately in size-exclusion chromatography experiments (SEC), elution volumes of 
TDH and KBL indicated that they exist in dimeric forms in solution (Supplementary Table 2). The TDH 
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results were therefore consistent with the findings gained by X-ray crystallography.  Interestingly, 
when mixed and assayed together, TDH and KBL co-eluted predominantly at a volume suggesting 
the existence of the proteins as monomers. Miniscule amounts of both proteins eluted at a volume 
corresponding to a large oligomer of approximately 188 kDa , but the low protein concentrations 
make this observation inconclusive. Overall, the SEC findings confirm the dimeric structure of TDH. 
Additionally, an indication of potential interactions between TDH and KBL was obtained, however 
further study is required to confirm the dissociation of TDH and KBL dimers or the existence of a 
TDH:KBL complex. 
 
The cross-linking studies carried out using dimethyl suberimidate (DMS) provide more evidence in 
regards to the oligomeric states of TDH and KBL.  SDS-PAGE analysis of the samples revealed protein 
bands representing monomeric and dimeric forms of TDH and KBL (Supplementary Figures 6-8).  A 
single two-fold dilution of the concentration did not have an effect on the apparent oligomeric 
states detected by the cross-linking experiments.  Experiments conducted with TDH and KBL 
together do not suggest that the two proteins are complexed in solution, as there are no additional 
bands present (Supplementary Figure 6, lanes 7 and 8), compared to when samples of the two 
proteins were tested separately (Supplementary Figure 6, lanes 1, 2, 4 and 5). The pull-down assay 
using His-tagged KBL and native TDH was in agreement with the data from the cross-linking studies 
and the majority of the SEC studies, suggesting that TDH and KBL do not appear to form a complex 
with each other in solution. When His-tagged KBL was applied to the Ni-NTA column, non-tagged 
TDH washed through with the wash buffer. Meanwhile, KBL was retained on the column, and elution 
with the 250mM imidazole elution buffer caused KBL to elute alone, demonstrating that the two 
proteins had not bound to each other or remained bound to each other under the conditions tested 
(Supplementary Figure 9). 
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Structural	insights	into	ligand	binding	and	catalysis	
To gain a complete picture of TDH structure as it relates to function, various ligands, including the 
natural substrates, were co-crystallised with TDH prior to obtaining diffraction data.  As can be seen 
in Figure 6 and Figure 7, the TDH substrates, NAD+ and L-threonine, occupy a deep cleft in the 
protein. The L-threonine binding pocket and the pocket occupied by the nicotinamide group of NAD+ 
are partially separated by the side chain of Met81 (Figure 7). 
NAD binds TDH through a combination of hydrogen bonds and hydrophobic interactions with several 
main chain and side chain atoms of TDH residues. Whilst the nicotinamide and the adjacent ribose 
groups bind in deep pockets of the protein, the remainder of the NAD molecule faces the exterior. 
The interactions with important TDH residues are displayed in Figure 6b. In addition, the cofactor 
also hydrogen-bonds with several water molecules. This is particularly the case for the phosphate 
groups, the ribose hydroxyl groups and the nicotinamide amide (Figure 6a). 
 
Figure 6. Binding of NAD+ to TDH in 3D (a) and 2D (b) representations. In (a) hydrogen bonds are indicated by red lines; 
water molecules are depicted as red spheres. In (b) hydrogen bonds are indicated by dotted lines, whilst Van der Waals 
interactions are represented by green curved lines, with the corresponding TDH residues in green text. 
To gain insight into L-threonine binding, TDH was co-crystallised with the reduced form of the 
cofactor (NADH) to prevent turnover, which involves oxidation of the amino acid.  The L-threonine-
bound structure (PDB ID: 5K4W) at 1.72 Å resolution (Figure 7) reveals that the carboxyl group of L-
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threonine hydrogen-bonds with the side chain and main chain atoms of Ser82 and Thr186. The 
amine group of L-threonine is seen to hydrogen-bond with the side chain hydroxyl group of Thr186, 
with the nicotinamide carbonyl of NADH and with a nearby water molecule. The side chain hydroxyl 
group of L-threonine is hydrogen-bonded to Thr119 and Tyr144, whilst the methyl group is directed 
towards the hydrophobic amino acid Trp280. This aligns the β-carbon with the C4 atom of the 
nicotinamide ring (discussed in more detail below). Another interesting feature of this structure was 
that the flexible loop, Loop 1, is closed over the active site, meaning that it is completely shielded by 
the enzyme (Figure 7c). This was the case in both TDH monomers in the asymmetric unit of the 
structure, both of which were bound to NADH and L-threonine. 
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Figure 7. Binding of L-threonine to TDH in 3D (a) and 2D (b) representations, derived from structure 5K5W. In (a) 
hydrogen bonds are indicated by red lines, electron density of L-threonine is represented by a blue mesh and a water 
molecule is depicted by a red sphere. In (b) hydrogen bonds are indicated by dotted lines, whilst Van der Waals 
interactions are represented by green curved lines, with the corresponding TDH residues in green text. (c) shows a 
surface representation of threonine-bound TDH derived from PDB ID: 5K4W; the surface of loop 1, which is closed over 
the active site, is coloured red and is semi-transparent. 
X-ray crystallographic structures of TDH bound to compounds reported to be inhibitors, L-allo-
threonine[28] and pyruvate[21,29], were also successfully solved.  These compounds were shown to 
occupy the L-threonine binding site, forming interactions with some of the same active site residues 
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as the natural TDH substrate, thereby demonstrating their modes of inhibition  (Supplementary 
Figure 10). 
 
 
The putative mechanism of reaction of TDH involves transfer of a hydride from the β-carbon of L-
threonine to the C4 atom of the nicotinamide ring[20]. The data presented here confirm that the 
atoms involved in this reaction are well aligned and at a distance that would permit such a reaction 
to happen (Figure 7).  X-ray structures described herein confirmed the presence and interaction of 
key putative catalytic residues, such as Thr119, Tyr144 and Thr186 ( Figure 7).  Another structural 
feature that is conserved in SDRs and deemed important for catalysis is a chain of water molecules 
that is believed to form a proton relay that transfers the proton extracted from L-threonine to the 
bulk solution, allowing the enzyme to catalyse another reaction. This water chain requires a certain 
orientation of residues to bind the water molecules. The feature observed in several SDRs is an 
interaction between an asparagine side chain and the main chain of another residue. In this case, the 
interaction occurs between Asn96 and Ile80 (Figure 8a), causes a kink in the α-helix spanning 
residues Pro89-Lys109 and changes the orientation of the Asn96 carbonyl group. This allows the 
Asn96 carbonyl group to hydrogen-bond one of the water molecules in the water chain (Figure 8b). 
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Figure 8. Interaction between Asn96 and Ile80 (a), enabling hydrogen bonding of a water atom in a larger chain of 
hydrogen-bonded water molecules (b). Hydrogen bonds are indicated by red lines; water molecules are depicted as red 
spheres. 
The sidechain of Lys129 in TbTDH hydrogen-bonds with Asn282 and may have a stabilising role in 
this region of the enzyme, which is located on the exterior, behind the active site (Supplementary 
Figure10).  Lys129 corresponds to Arg180 in the homologous murine TDH (Supplementary Figure 
11).  An R180K variant of this enzyme has been shown to have reduced thermostability and impaired 
recognition of L-threonine , as indicated by reduced catalytic efficiency[30].  Inspection of the 
structure suggests that replacement of arginine with lysine in TbTDH and bacterial TDH probably 
results in relatively fewer interactions with surrounding residues, and thus, a weaker stabilising 
effect. 
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Other	features	observed	in	crystallographic	models	
A number of molecular species from the storage buffer and from the crystallisation solutions were 
found to co-crystallise with TDH; glycerol, acetate, sulphate and sodium ions were all observed in 
TDH structure models. These molecules occupied various positions, and a few positions were 
occupied in a consistent manner and observed in multiple structures. Most notably, glycerol and 
acetate bound within the L-threonine binding site (Supplementary Figure 12). Glycerol was also 
found to bind to the same regions in different TDH models (Supplementary Figure 13). 
Typically, different TDH dimers in each of the solved structures are separated from other monomers 
by an ordered array of water molecules. However, one direct interaction between two monomers in 
separate dimers was observed in one model (PDB ID: 5K50). Interestingly, the interaction is formed 
between residues of the flexible Loop 2 region (Supplementary Figure 14). The interaction does not 
appear to be strong enough to be an important physiological interaction and is likely to be a result of 
the crystallisation process. 
 
Geometric	Simulations	
Noncovalent	constraint	identification	using	FIRST	
We have examined the dimeric crystal structures using FIRST, which identifies noncovalent polar and 
hydrophobic interactions and assesses their effect in rigidifying the structure. FIRST identifies a well-
formed network of hydrophobic tethers, hydrogen bonds and salt bridges in the dimer interface 
region, consistent with the PISA analysis. These interactions do not, however, make the dimer into a 
rigid unit; instead, flexibility remains, consistent with the observed differences between the apo, 
holo, and threonine-bound crystal structures. The Loop 1 region appears not to be constrained by 
any noncovalent interactions; this is consistent with the crystallographic observations of flexibility in 
this region. 
25 
 
 
Low-frequency	flexible	motion	identified	using	Elnemo	and	FIRST/FRODA	
We have identified low-frequency mode eigenvectors using coarse-grained elastic networking with 
the Elnemo software, and we have carried out all-atom simulations of flexible motion using the 
FRODA geometric simulation software (incorporated in FIRST) to explore motion biased along these 
low-frequency mode directions. The most intriguing large-scale motion we identify is that along the 
lowest-frequency nontrivial mode of motion (Elnemo's mode 7: modes 1-6 are trivial rigid body 
motions). This motion is predominantly a twisting motion about an axis running perpendicularly 
through the dimer interface, i.e. as if the dimer were being twisted about its long axis. The motion is 
easily permitted by the constraints in the interface region, with large amplitudes of motion (several 
Å RMSD) being achieved in the geometric simulations; the long flexible sidechains which form the 
inter-dimer interactions easily accommodate the motion. The character of this motion is essentially 
identical for the apo, holo and L-threonine-bound forms. 
 
Figure 9. Geometric simulations of apo-TbTDH along Elnemo’s mode 7: (a) overlay of multiple projections of apo-TbTDH 
conformations, superposed on holo- (gold) and L-threonine-bound (dark red) TbTDH, with arrows indicating direction of 
the twisting motion; (b) superposition of holo-TbTDH (gold) over a projection of the apo form conformation (fitted 
backbone RMSD = 0.49 Å); (c) superposition of L-threonine-bound TbTDH (dark red) over a projection of the apo form 
conformation (backbone fitted RMSD = 0.63 Å). 
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This twisting motion appears to account for most of the global differences observed between the 
apo, holo, and L-threonine-bound forms of the dimer. The holo and L-threonine-bound forms can be 
superimposed on the apo form with fitted backbone atom RMSDs of 1.13 and 1.582, respectively. 
However, the geometric simulation of motion of the apo form biased along the lowest-frequency 
nontrivial mode generates a conformation which resembles the holo form more closely, with a fitted 
backbone atom RMSD of 0.49 Å, and, shortly thereafter, a conformation which resembles the L-
threonine-bound form, with a fitted backbone atom RMSD of 0.63 Å. These superpositions are 
shown in Figure 9.  Simulations beginning from the holo and L-threonine-bound forms (not shown) 
give consistent results and visit states closely resembling the apo form. 
Random	(diffusive)	motion	in	the	flexible	Loop	1	region	
To assess the freedom of motion in Loop 1, which as noted is not restrained by any identifiable 
noncovalent interaction, we have carried out unbiased geometric simulations of random diffusive 
motion in the protein starting from the apo state. In one such simulation, the residues making up 
Loop 1 were observed to drift from their initial "open" state to a much more "closed" state, as 
shown in in Figure 10. This confirms that the loop has the conformational freedom required to visit 
both open and closed states regardless of the binding of substrate, and is suggestive of a 
conformational-selection mechanism rather than a directly induced-fit mechanism of active site 
closure by Loop 1. 
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Figure 10. Overlays of multiple states of apo-TbTDH during simulations of random diffusive motion.  The arrow indicates 
the direction of progressive movement of Loop 1 (in gold) during the simulation.  States showing extremes of the Loop 1 
position are in solid colour, whilst intermediate states are translucent. 
Discussion	
TbTDH	as	a	GalE-like	TDH	
TbTDH is a GalE-like TDH, sharing many features with the enzymes from F. frigidimaris (FfTDH), C. 
necator (CnTDH) and T. volcanium (TvTDH) (20–22,32).  We have shown that TbTDH possesses 
features that are conserved amongst these enzymes, as well as other enzymes within the SDR 
enzyme superfamily: a monomeric length of around 320 residues, a glycine-rich region (GxxGxxG) 
within the NAD-binding domain, a structural motif including lysine and tyrosine (YxxxK) near the 
active site, and several other conserved active site residues (Figure 7).  These features contrast with 
those in TDH in other species, such as E. coli, Pyrococcus horikoshii and Thermococcus kodakarensis, 
which are homotetramers from a different class of enzyme, rather than homodimers, and which 
specifically bind divalent metal cations such as zinc[8,17,31].   
Another distinguishing feature of GalE-like TDHs is the presence of a loop adjacent to the active site 
which is directly followed by a motif represented by the sequence GTTDY[21].  In TbTDH, this 
‘flexible Loop 1’ is followed by a similar sequence, GATDY, but it is unclear if this confers any 
structural or functional  difference between these and the other known GalE-like TDHs. Overall, the 
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structural characteristics observed place TDH in the ‘extended’ category of SDRs (eSDR), and thus 
the enzyme is assigned the identifier SDR14E under the SDR nomenclature initiative[32]. 
 
TbTDH	conformational	flexibility	
Conformational	variability	
Figures 3, 4 and 9 indicate the various regions of flexibility and dynamic behaviour that TbTDH may 
possess in solution.  Comparisons of different X-ray crystallographic structures and the geometric 
simulations show that global motions in the TDH homodimer consist of a combination of hinge and 
shear motions, where the two subunits appear to twist in opposite directions about the dimer 
interface.  These conformational variations are likely to predominate, as exemplified by the fact that 
the models arising from various geometric simulations can be superimposed over crystallographic 
structures of both apo- and holo-TbTDH.  Other important conformational changes may involve 
alterations in the relative positions of the NAD-binding and catalytic domain. 
Recent studies on other dimeric enzymes[33,34] have shown that low-frequency motions can be 
intimately involved in the opening and closing of enzyme active sites. In the case of TbTDH, however, 
the lowest-frequency motion gives a good description of the global differences among the 
apo/holo/threonine-bound series of structures, but the motion has no particular effect on the active 
site geometry. It is therefore plausible that the different degrees of twisting in the different dimer 
structures represent states from a broad conformational ensemble of flexible variation, selected by 
crystallisation conditions; the twisting motion may not be directly related to the enzyme function. 
The most obvious regions of conformational variability in TbTDH are the flexible Loops 1 and 2.  
Whereas it is unclear whether Loop 2 has any functional role, it appears that Loop 1 may have an 
important role in substrate binding.  This will be discussed in more detail below. 
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Substrate	binding	and	catalytic	Mechanism	of	Action		
The NADH- and L-threonine-bound structure presented here (Figure 7) is only accompanied in the 
literature by one other threonine-bound wild-type TDH structure[35]. Both structures provide 
valuable insights into the proposed mechanism of action of TDH, in which a hydride is transferred 
from the β-carbon of L-threonine to the C4 atom of the nicotinamide ring of NAD+; both L-threonine 
and the co-factor are bound in the necessary orientation for catalysis.  Furthermore, the 
nicotinamide ring was bound in a syn conformation, meaning that the hydride is transferred to the 
pro-S position on the C4 carbon.   
The residues of the “catalytic triad”[36,37], which have been described in alcohol dehydrogenases 
(ADH) and SDRs in general, have been identified as Thr119, Tyr144 and Lys148 in TDH.  The residues 
Thr119 and Tyr144 appear to hydrogen-bond the side chain hydroxyl group of L-threonine.  The 
interatomic distances between the oxygen atoms of the relevant groups on L-threonine and Tyr144 
also seem to support the hypothesis that Tyr144 acts as a base and withdraws a proton from the 
substrate.  Molecular dynamics simulations in Drosophila ADH have demonstrated that this is made 
possible by the fact that the protonation states of the active site tyrosine and lysine residues are 
coupled(36–38).  Extrapolating this theory to the TDH mechanism of action, the lysine residue 
(Lys148 in TbTDH) extracts a proton from a hydroxyl group on a NAD ribose group, which in turn 
extracts the proton from the tyrosine residue, thus allowing it to extract the proton from L-
threonine.  In ADH, this proton is then proposed to be transferred to a chain of eight water 
molecules, which relay the proton until it is removed from the interior of the enzyme.  In this way, 
the tyrosine residue is deprotonated again and is able to participate in the catalysis of another 
reaction[38,39].  The interatomic distances between the relevant groups observed in TDH structure 
models all seem to lend support to this theory.  The pH dependence of the protonation state of 
lysine and tyrosine may also explain why the optimum pH in TbTDH(unpublished research) and other 
GalE-like TDHs is around pH 8-9[4,21,22,29,40–43].  A short chain of water molecules close to Lys148 
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was identified in several of the TbTDH structures obtained here, but a complete chain of eight water 
molecules, which has been shown to be essential for ADH activity[39], was not observed.  It is 
possible that a shorter water chain is sufficient for activity in TDH.  Alternatively, it may be that the 
conformational state of TDH in which this water chain is complete has not been captured in any of 
the crystallographic models to date. 
 
Loops analogous to the flexible Loop 1 identified in TbTDH have been highlighted in TDH from other 
species[20,35]. Indeed, the amino acid sequence corresponding to the loop appears to be a 
conserved feature among GalE-like TDHs.  The studies here provide crystallographic evidence of 
distinct conformations adopted by Loop 1 which are characterised by a dramatic shift of 
approximately 5 Å in distance.  In the X-ray crystallographic structures of TbTDH, Loop 1 was 
observed in the ‘open’ conformation and the ‘closed’ conformation in a number of contexts, 
including in cofactor-bound structures, and structures bound to a cofactor plus L-threonine or 
another ligand.   
Although the data are not conclusive, one can hypothesise that Loop 1 can be in an open or closed 
conformation, regardless of whether a substrate is bound in the L-threonine binding site or not.  It is 
possible that a change to a closed conformation is induced by binding of a ligand to the L-threonine 
binding site, as was observed with L-threonine- and pyruvate-bound structures.  However, one 
structure (PDB ID: 5K50) shows that binding of L-allo-threonine did not induce a closed 
conformation.  The observation that different Loop 1 conformations can be adopted in different 
subunits of the same TDH dimer (as observed in PDB ID: 5K4U [Supplementary Figure 15]) suggests 
that the Loop 1 conformation in each monomer is adopted independently of the conformation in the 
other subunit.  The random walk geometric simulations of TbTDH indicate that the loop may have 
some conformational freedom due to a lack of restraints on this motif.  Alternatively, there may be a 
mechanism whereby the conformation of one subunit affects the conformation in the other subunit.  
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He et al. proposed that the residue Arg180 in MmTDH, which corresponds to Lys129 in TbTDH, may 
act as a remote “switch” between the open and closed forms of TDH[30].  Although these residues 
are not located in regions of conformational variability (Figure 3 and Figure 4), Lys 129 does interact 
with Asn282, which is in close proximity to the flexible region at residues 255-275.  Further 
investigation will be required to understand if Lys129 plays a role in the stability and catalysis of TDH 
from T. brucei. 
Considering the effect that it has on the active site of TDH, it is possible that Loop 1 plays an 
important role in the mechanism of TDH binding to its ligands.  The loop may remain open before 
and after NAD+ binding to accommodate L-threonine, but then close over the active site once L-
threonine is bound. Recently, data from studies of TDH from C. necator have also demonstrated that 
this loop region adopts different conformations in ‘open’ and ‘closed’ structures of TDH.  Using a 
combination of crystallographic data from apo and holo forms of CnTDH, molecular dynamics 
simulations and enzyme kinetics were used to build a hypothesis of ligand binding and structural 
changes in this enzyme. Nakano et al. proposed a model whereby NAD+ binding caused a 
rigidification of flexible regions in the NAD-binding domain, but the flexible loop remained open.  
Then, in the same model L-threonine binding causes Loop 1 to close over the active site, and this 
accounts for the selectivity of the enzyme for L-threonine[35]. 
These findings are in some agreement with those presented herein, which suggest that changes in 
the conformation of Loop 1 and the catalytic domain of TbTDH happen in response to L-threonine 
binding.  The findings of Nakano et al. also support the existence of an induced fit mechanism of 
ligand binding for TDH, as Loop 1 seems to form a “lid” over the L-threonine active site, something 
that would prevent L-threonine binding if it happened prior to its encounter with the enzyme.  Some 
researchers assert that all enzymes that form a lid over their active sites must act by induced fit 
mechanisms[44]; the findings on TDH structure would seem to illustrate this well.  However, some 
structures presented herein show that TbTDH can adopt a ‘closed’ conformation in the absence of L-
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threonine (e.g.  PDB ID: 5K4V or PDB ID: 5K4U; see Table 1).  Furthermore, rigidity analysis and 
geometric simulations of apo-TbTDH suggest that Loop 1 has the conformational freedom to enter 
the closed state in the absence of ligands.  Therefore, in the case of TbTDH, an induced fit 
mechanism may occur as part of the wider process of conformational selection, which has been 
proposed as a way in which proteins with variable conformations can adopt the necessary state 
required to carry out a function[45].  Although the flexibility of Loop 1 may be linked to the 
selectivity of TDH for binding and catalysis of L-threonine, the possibility that the enzyme may 
sample several different conformations in solution may allow a greater variety of ligands to bind, 
beyond analogues of the natural substrates.  This could have significant implications for drug 
discovery efforts involving TDH as a target. 
 
Interaction	between	TDH	and	KBL	
The evidence pertaining to the existence of a TDH:KBL heterodimer is inconclusive.  Although, under 
one condition of the SEC experiments, there appeared to be a high molecular weight species that 
may be attributed to TDH and KBL, the low concentrations of the enzymes in the corresponding 
fraction make this result uncertain.  In addition, X-ray crystallography, cross-linking studies and the 
pull-down assay all failed to find evidence to confirm a stable association between TDH and KBL.   
Although it has been suggested that TDH:KBL complex formation would facilitate transfer  of the 
unstable AKB between the two enzymes[8,13], Marcus and Dekker have demonstrated the AKB 
decarboxylation is pH-dependent and that its half-life could be extended to 11 minutes at pH 7.5, or 
up to 140 minutes at pH 11.1[46].  This would negate the requirement for TDH and KBL to form a 
complex.  Subjects for future investigation include the influence of ligand binding and catalysis on 
oligomerisation of TDH and KBL individually, and together in the same environment.  
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In this study, the structure of TbTDH has been described in detail, providing insights into the 
dynamic behaviour of the enzyme and how this may relate to its function.  The relationship between 
the enzyme and its natural substrates has been highlighted, and the possible interaction between 
TDH and KBL has been explored.  This new information will contribute to the interpretation of 
further functional data on TDH, which could in turn help to guide drug discovery efforts.  
Furthermore, these findings add to the knowledge-base of the related enzymes of the SDR family. 
Methods	
Materials	and	Methods	
Expression	and	Purification	
The genes for TDH and KBL were amplified by PCR from T. brucei genomic DNA and cloned into the 
NdeI and BamHI sites of the E. coli expression vector pET15b using standard methods and then 
expressed in E. coli. The protein was then purified from the supernatant solutions extracted from cell 
lysates using nickel affinity chromatography, employing a HisTrap HP (GE Healthcare) to isolate His-
tagged protein.  Purity of protein solutions was determined by SDS-PAGE and by size-exclusion 
chromatography (SEC).  SEC was performed on a Superdex 200 10/300 GL column (GE Healthcare), 
testing 200-400μl samples using Fast Performance Liquid Chromatography (FPLC) (Pharmacia 
Biotech) at a flow rate of 0.5ml/min and a maximum pressure of 1.5 MPa. Before any experimental 
samples were run, the column was calibrated according to the manufacturer’s instructions with the 
standards.  Protein elution volumes (Ve) were determined by following UV absorbance at 280 nm 
(A280).  The void volume (Vo) of the column was determined by running a sample of Blue dextran 
(MW 2000 kDa), which is not retained by the resin, due to its size.  TDH and KBL were identified by 
using a standard calibration curve to predict the molecular weights of proteins eluting at a particular 
elution volume, with confirmation by SDS-PAGE. 
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Where it was desired to improve the purity of the protein solutions after affinity chromatography, 
ion-exchange chromatography (IEC) was employed.  Appropriate conditions for IEC were determined 
by using the ProtParam tool on the ExPASy server to predict the isoelectric points of TDH and KBL 
from their amino acid sequences. IEC was performed on a 250ml Q-sepharose column using an ÄKTA 
Prime (GE Healthcare) FPLC machine.  Protein was purified by eluting with a gradient of 1000ml 
solvent progressing from low salt buffer (100 mM NaCl) to high salt buffer (1 M NaCl). 
 
TDH and KBL solutions were stored in ice baths and refrigerated at 2-8°C.  The proteins appeared to 
be able to be stored in this way for at least one month without an appreciable loss in function.  
Alternatively, solutions were stored for longer periods, frozen at -20°C, and loss of function was not 
observed after several months of freezing the proteins. 
 
 
X-ray	crystallography	
Crystallisation	
Proteins were crystallised by use of the hanging drop method, using commercial crystallisation 
screens or manually prepared solutions (Table 1), as previously described. 
Cocrystals of the proteins with substrates, inhibitors and metal ions were prepared using the same 
method, or crystals were soaked in solutions containing additional substances of interest for a 
period of 5 minutes to 1 hour. 
As described previously, prior to data collection, crystals were harvested using a fabric or plastic loop 
and cryo-cooled by one of three methods: the loop and crystal were plunged directly into a bath of 
liquid nitrogen; the loop and crystal were suddenly exposed to a stream of cryo-cooled nitrogen gas; 
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the loop and crystal were plunged into liquid ethane for one second and then into liquid nitrogen.  
As cryo-cooling presents the risk of causing damage to crystals, cryoprotectants such as glycerol, 
ethylene glycol or PEG 400 were sometimes added.  In these cases, crystals were transferred to a 10 
µl drop of crystallisation well solution and four 1 µl drops of cryoprotectant were sequentially mixed 
into this solution before the crystal was cryo-cooled as described above. 
 
Data	collection	and	structure	solution	
X-ray data were collected at synchrotron radiation sources, the European Synchrotron Radiation 
Facility (ESRF) and Diamond Light Source (DLS). Early data processing was either carried out 
manually or by use of the integrated data reduction pipeline, xia2[47], at DLS.  When early data 
processing was carried out manually, data integration was carried out using iMosflm[48]. When 
automated processing was carried out by xia2, the program XDS was used.  Space group 
determination was initially attempted by selecting from iMosflm-provided options, or it was carried 
out automatically using POINTLESS[49,50]. Scaling and merging were carried out using Scala[49] or 
Aimless[51],together with ctruncate[52] to convert the intensities into structure factors. As an 
analogous TDH structure was already available in the PDB, phase determination for all TDH 
structures described herein was carried out by means of molecular replacement, using 
Molrep[53,54] or Phaser(174).  In order to know the appropriate number of molecules per 
asymmetric unit, Matthews_coef[55] was used. Refinement was performed using Refmac5[56,57]. 
To incorporate ligands into the model, their structures were produced as .pdb files, along with 
restraints (stored in .cif files, used by Refmac), using the online ProDRG server[58].  Once positioned 
correctly, in accordance with its associated electron density, ligand files were merged with protein 
.pdb files. 
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The structure visualisation and manipulation software, Coot[59,60], was used on Windows and Linux 
systems to carry out real space refinement and validation of structures. Manipulation of structures 
was guided by 2Fo-Fc maps at σ levels of 1.5 and by Fo-Fc maps at σ levels of 2.00.  
To validate models, bond distances and geometries, including those in hydrogen bonding networks, 
were observed visually and modified accordingly. The Ramachandron plot function in Coot was used 
to find and correct errors in the phi (φ) and psi (ψ) angles of amino acid residues.  Coot’s rotamer 
analysis tool was also used to correct side chain orientations in TDH structures. 
 
Structural	Analysis	
Sequence	Analysis	
Nucleotide and amino acid sequences from TbTDH (Tb927.6.2560) were compared with those of 
TDH from other organisms using the National Center for Biotechnology Information (NCBI) Basic 
Local Alignment Search Tool (BLAST)[61].  Certain evolutionarily conserved sequences were also 
identified in the 2D sequences and visually using Coot and other visualisation software, such as UCSF 
Chimera[62]. 
 
3D	structure	
Protein structure models and their interactions with ligands were observed visually using PyMOL 
(Schrödinger LLC), Coot and UCSF Chimera(182). To analyse conformational variability evident in 
various TbTDH structures, eight representative monomers from solved structures were compared in 
a method similar to Huntington [63]. The CCP4 program baverage was used to calculate average B-
factors per residue for all main chain atoms.  UCSF Chimera was used to visualise the mean B-factors 
and the RMSDs calculated between alpha carbons of the eight structures when superimposed.  
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The program PISA (Protein Interfaces, Surfaces and Assemblies)[27] in the CCP4 package was used to 
output the quaternary structures of TDH models for further analysis.  
Geometric	simulations	of	flexible	motion	
Amplitudes of motion in models of TDH were simulated using a combination of rigidity analysis and 
coarse-grained elastic network normal mode analysis, as described previously[33,64]. Elnemo 
software is used[65] to obtain normal mode eigenvectors from coarse-grained elastic network 
modelling, and FIRST/FRODA software [66,67] to carry out rigidity analysis (FIRST)[68], identifying 
the noncovalent interaction network and labelling dihedral angles as locked or variable, and 
template-based geometric simulations of flexible motion (FRODA)[67] which project the all-atom 
structure over large amplitudes of motion while maintaining local bonding and steric geometry. 
Normal mode eigenvectors were generated in Elnemo in a one-site-per-residue coarse-graining 
using the Cα geometry of the input structure, placing springs of equal spring constant between all 
sites lying within an interaction distance cut-off of 12 Å.  A rigidity analysis of the all-atom input 
structure is carried out in FIRST using the "pebble game" algorithm [66,69] which matches degrees 
of freedom against bonding constraints in the molecular framework of the protein. Bonding 
constraints include covalent, hydrophobic and polar (hydrogen bond and salt bridge) interactions. As 
the strength of the polar interactions can be gauged from their geometry, the results of the analysis 
depend on an "energy cut-off" which selects the set of polar interactions to include in the constraint 
network[68]. A cut-off of -2.0 kcal/mol is used in this study. 
Template-based geometric simulation of flexible motion, carried out using FRODA, explores the 
mobility of the all-atom structure by iterative perturbation and relaxation of atomic positions in 
parallel and antiparallel to the direction of normal-mode eigenvectors. Several thousand iteration 
steps are carried out to generate large motion amplitudes. The simulation generates an initial phase 
of "easy" motion, where the bonding geometry is easily maintained, followed by the onset of 
"jamming" as the motion encounters steric and bonding constraints which naturally limit its 
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amplitude. The conformational changes of geometric simulations of TDH projected using this 
method were observed and compared with superpositions of crystallographic models in PyMOL and 
UCSF Chimera. 
Other	biochemical	techniques	
Size-exclusion	chromatography	
SEC was used as described above to predict the oligomeric states of TDH and KBL.  Before any 
experimental samples were run, the column was calibrated with the standards: β-amylase (MW 200 
kDa), alcohol dehydrogenase (MW 150 kDa) bovine serum albumin (BSA) (dimer MW 132 kDa; 
monomer MW 66 kDa), ovalbumin (MW 45 kDa), carbonic anhydrase (MW 24 kDa) and cytochrome 
C (12.4 kDa).  To estimate the molecular weights of proteins eluting at a particular elution volume 
(Ve), a plot of log10 molecular weight of standard protein against the elution volume: void volume 
ratio (Ve/V0) was made using Microsoft Excel. A number of experiments testing TDH and KBL in 
isolation, together and in the presence of substrates were carried out to measure changes in the 
observed elution volumes and oligomeric states predicted by linear regression analysis. 
 
Cross-linking	
Cross-linking studies of TDH and KBL were carried out using a method similar to that of Davies and 
Stark[70], which employed dimethyl suberimidate (DMS) as the cross-linking agent. As cross-linking 
reactions predominate within oligomers, this was used to provide an indication of the oligomeric 
states of TDH and KBL. Protein concentrations and DMS concentrations were carefully chosen to 
avoid precipitation.  
All solutions were made up to 50μl or 100μl in 200mM Tris.HCl buffer at pH 8.5. Final protein 
concentrations were approximately 1mg/ml. Reactions were carried out in duplicate, at room 
temperature and at 2-8°C. The samples were incubated for 3 hours or overnight and the reactions 
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were then halted by the addition of Laemmli buffer in preparation for analysis by SDS-PAGE. Gels of 
9% polyacrylamide, rather than the usual 12%, were used to increase the migration of higher 
molecular weight complexes. 
 
Accession	numbers	
Coordinates and structure factors for all structures cited herein have been deposited in the Protein 
Data Bank with the following accession numbers: 5L9A; 5LC1; 5K4Q; 5K4T; 5K4V; 5K4U; 5K50; 
5K4W; 5K4Y. 
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